Related Experiment Video
Updated: Apr 14, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
MR-PET evaluation of 1-month post-ablation therapy for hepatocellular carcinoma: preliminary observations
Miguel Ramalho1, Mamdoh AlObaidy, Lauren M Burke
1Department of Radiology, University Of North Carolina at Chapel Hill, CB 7510, 2001 Old Clinic Bldg., Chapel Hill, NC, 7599-7510, USA.
Purpose:
The purpose of the study was to evaluate the feasibility and protocol optimization of whole-body hybrid MR-PET system performed 1-month after post-locoregional thermoablative procedures for hepatocellular carcinomas (HCCs).
Materials And Methods:
Eight patients (6 men and 2 women; mean age, 56.6 ± 5.5 years) with 9 ablated HCCs constituted our study population. Three readers interpreted the studies to determine the presence or absence of residual malignancy. Two readers independently assessed the fused MR-PET images to compare registration accuracy of two types of T2-weighted (triggered T2 half-Fourier acquisition single-shot turbo spin-echo and turbo spin-echo) and T1-weighted [Cartesian and radial 3D gradient echo (GRE)]. Image quality evaluation of both 3D-GRE T1-weighted sequences was evaluated. Kappa statistics were used to measure inter-observer agreement. Non-parametric Kruskal-Wallis and Wilcoxon signed-rank tests were used for qualitative data analysis.
Results:
Definite residual tumor was observed in 3/9 ablations; two were PET positive. All residual tumors were isovascular on MRI. Radial 3D-GRE demonstrated significantly superior MR-PET subjective co-registration in comparison with the remaining sequences and showed a non-significant trend toward higher image quality scores than Cartesian GRE.
Conclusion:
Whole-body hybrid MR-PET is feasible as a part of 1-month follow-up post-locoregional thermoablative treatment for HCC. Radial 3D-GRE offers improved co-registration with PET data, with overall good image quality.

